Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 11/20 | 0.78 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | ACP1 | P24666 | 3/20 | 0.43 |
| ▸ | PDE5A | O76074 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4251032 | 0.90 | ADORA1 (0.87) | ADORA1ADORA2AADORA3ADORA2BACP1 | |
| SCHEMBL4251034 | 0.90 | ADORA1 (0.87) | ADORA1ADORA2AADORA3ADORA2BACP1 | |
| SCHEMBL4251031 | 0.90 | ADORA1 (0.87) | ADORA1ADORA2AADORA3ADORA2BACP1 | |
| SCHEMBL15425807 | 0.84 | ADORA1 (0.81) | ADORA1ADORA2AADORA3ADORA2BACP1 | |
| SCHEMBL15426758 | 0.82 | ADORA1 (0.77) | ADORA1ADORA2AADORA3ADORA2BACP1 | |
| SCHEMBL15425800 | 0.80 | ADORA1 (0.74) | ADORA1ADORA2AADORA3ADORA2BACP1 | |
| SCHEMBL15426757 | 0.80 | ADORA1 (0.74) | ADORA1ADORA2AADORA3ADORA2BACP1 | |
| SCHEMBL4256817 | 0.79 | ADORA1 (0.69) | ADORA1ADORA2AADORA3ADORA2BACP1 | |
| SCHEMBL8355377 | 0.79 | ADORA1 (0.62) | ADORA1ADORA2AADORA3ADORA2BACP1 | |
| SCHEMBL15425805 | 0.78 | ADORA1 (0.70) | ADORA1ADORA2AADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | ADORA3, ADORA2A, ADORA1 | ADORA1 3/4885ADORA2A 2/4885ADORA3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.